On Tuesday, Shares of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), subtract -1.91% and shut at $13.35 inside the end purchasing and offering session. The last exchanging scope of the stock ranges amongst $13.21 and $13.88. ARIAD Pharmaceuticals, Inc. (ARIA), a rare cancer-focused innovative biotechnology company, recently declared that clinical data on brigatinib, its investigational anaplastic lymphoma kinase (ALK) inhibitor, will be presented at the International Association for the Study of Lung Cancer (IASLC) 17th World Conference on Lung Cancer (WCLC) being held in Vienna, December 4 to 7, 2016.
“We are excited that updated data from the ALTA trial on brigatinib in patients with ALK-positive non-small cell lung cancer will be presented at WCLC this year. We continue to be encouraged by the activity and safety profile seen in the ALTA trial, and especially the correlation between investigator and independent review assessments of response and response durability. ALTA data to be presented at the meeting will include about three months of additional follow-up as contrast to the abstract,” stated Timothy P. Clackson, Ph.D., president of research and development and chief scientific officer at ARIAD.
Shares of Companhia Siderurgica Nacional (ADR) (NYSE:SID), added 8.82% and shut at $3.70 inside the last exchanging session. The rest of the purchasing and offering scope of the stock levels among $3.47 and $3.72. The association’s commercial center capitalization is $5.44 Billion with the general uncommon loads of 1.36 billion. Companhia Siderurgica Nacional (BM&FBOVESPA: CSNA3) (SID) declares its results for the third quarter of 2016 (3Q16):
R$1,239 million EBITDA generated, a 45% increase over 2Q16, with 26% EBITDA Margin.
The Gross Profit registered RS1,311 million during 3Q16, 42% higher than 2Q16. The gross margin reached 30%, 9p.p. above 2Q16.
Steel EBITDA of R$552 million, with 19% EBITDA margin, 49% higher than 2Q16, showing the recovery of the steel sector in the domestic market.
Increase in steel sales in the domestic market. 62% participation vs. 53% during 2Q16.
8% steel price increase in the domestic market.
Iron Ore Sales of 10.2Mt, 7% higher than 2Q16.
Iron ore FOB price reached US$39/t, 28% higher than 2Q16.
Mining EBITDA of R$599 million, with 46% EBITDA Margin, 64% higher than 2Q16.
Adjusted net debt remained flat at R$25,842 million, while leverage fell by 0.9x, closing the quarter at 7.4x, as compared to 8.3x in 2Q16, thanks to raised EBITDA generation in the last 12 months.